Evidence map›Paper›PMID 39709425›Full record

ReviewRespiratory research2024

Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.

Katrin Haeussler, Afisi S Ismaila, Mia Malmenäs, Stephen G Noorduyn, Nathan Green, Chris Compton, Lehana Thabane, Claus F Vogelmeier, David M G Halpin

Abstract readReviewComparative Study
In one paragraph

Review in Respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katrin HaeusslerICON Health Economics, ICON Plc, Langen, Germany.ORCID http://orcid.org/0000-0002-3236-2028
Afisi S IsmailaValue Evidence and Outcomes, GSK, Collegeville, PA, USA. afisi.s.ismaila@gsk.com.ORCID http://orcid.org/0000-0002-2876-8308
Mia MalmenäsICON Health Economics, ICON Plc, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-2625-9198
Stephen G NoorduynDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.ORCID http://orcid.org/0000-0002-5936-5579
Nathan GreenDepartment of Statistical Science, University College London, London, UK.ORCID http://orcid.org/0000-0003-2745-1736
Chris ComptonGlobal Medical, GSK, Brentford, UK.ORCID http://orcid.org/0000-0002-7564-5343
Lehana ThabaneDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.ORCID http://orcid.org/0000-0003-0355-9734
Claus F VogelmeierDepartment of Medicine, Pulmonary and Critical Care Medicine, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany.ORCID http://orcid.org/0000-0002-9798-2527
David M G HalpinUniversity of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.ORCID http://orcid.org/0000-0003-2009-4406

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To optimize patient outcomes, healthcare decisions should be based on the most up-to-date high-quality evidence. Randomized controlled trials (RCTs) are vital for demonstrating the efficacy of interventions; however, information on how an intervention compares to already available treatments and/or fits into treatment algorithms is sometimes limited. Although different therapeutic classes are available for the treatment of chronic obstructive pulmonary disease (COPD), assessing the relative efficacy of these treatments is challenging. Synthesizing evidence from multiple RCTs via meta-analysis can help provide a comprehensive assessment of all available evidence and a "global summary" of findings. Pairwise meta-analysis is a well-established method that can be used if two treatments have previously been examined in head-to-head clinical trials. However, for some comparisons, no head-to-head studies are available, for example the efficacy of single-inhaler triple therapies for the treatment of COPD. In such cases, network meta-analysis (NMA) can be used, to indirectly compare treatments by assessing their effects relative to a common comparator using data from multiple studies. However, incorrect choice or application of methods can hinder interpretation of findings or lead to invalid summary estimates. As such, the use of the GRADE reporting framework is an essential step to assess the certainty of the evidence. With an increasing reliance on NMAs to inform clinical decisions, it is now particularly important that healthcare professionals understand the appropriate usage of different methods of NMA and critically appraise published evidence when informing their clinical decisions. This review provides an overview of NMA as a method for evidence synthesis within the field of COPD pharmacotherapy. We discuss key considerations when conducting an NMA and interpreting NMA outputs, and provide guidance on the most appropriate methodology for the data available and potential implications of the incorrect application of methods. We conclude with a simple illustrative example of NMA methodologies using simulated data, demonstrating that when applied correctly, the outcome of the analysis should be similar regardless of the methodology chosen.

Indexed as

Network Meta-Analysis as TopicPulmonary Disease, Chronic ObstructiveHumansRandomized Controlled Trials as TopicTreatment OutcomeBayesianBucher ITCChronic obstructive pulmonary diseaseFrequentistGRADEHead-to-head comparisonIndirect treatment comparisonNetwork meta-analysisRandomized controlled trialsSingle-inhaler triple therapy

Identifiers

PMID39709425
PMCPMC11663313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.